EN PL
PRZEDMOWA
 
 
REFERENCJE (15)
1.
Hamilton BK, Rybicki LA, Li H, et al. Tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate/mycophenolate for graft-versus-host disease prevention. Blood Adv 2023; 7: 4505-4513, DOI: 10.1182/bloodadvances.2023010310.
 
2.
Muanda FT, Blake PG, Weir MA, et al. Low-dose methotrexate and serious adverse events among older adults with chronic kidney disease. JAMA Netw Open 2023; 6: e2345132, DOI: 10.1001/jamanetworkopen.2023.45132.
 
3.
Mohamadou I, Savoye E, Cohen F, et al. Effect of hydroxychloroquine treatment on kidney allograft rejection and graft failure. Transplant Proc 2024; 10: S0041-1345(24)00327-0, DOI: 10.1016/j.transproceed.2024.05.027.
 
4.
Lentine KL, Lam NN, Caliskan Y, et al. Hydroxychloroquine and maintenance immunosuppression use in kidney transplant recipients: analysis of linked US registry and claims data. Clin Transplant 2020; 34: e14118, DOI: 10.1111/ctr.14118.
 
5.
Czarnecka P, Czarnecka K, Tronina O, Durlik M. Cytomegalovirus disease after liver transplant-a description of a treatment- resistant case: a case report and literature review. Transplant Proc 2018; 50: 4015–4022, DOI: 10.1016/j.transproceed. 2018.05.014.
 
6.
Ciszek M, Mucha K, Foroncewicz B, et al. Leflunomide as a rescue treatment in ganciclovir-resistant cytomegalovirus infection in a seronegative renal transplant recipient – a case report. Ann Transplant 2014; 19: 60–63, DOI: 10.12659/AOT.884035.
 
7.
Aldieri A, Chandran M, Matossian D, et al. Leflunomide as adjunct therapy for BK viremia management in pediatric kidney transplant recipients. Pediatr Transplant 2024; 28: e14724, DOI: 10.1111/petr.14724.
 
8.
Assadiasl S, Mojtahedi H, Nicknam MH. JAK inhibitors in solid organ transplantation. J Clin Pharmacol 2023; 63: 1330–1343, DOI: 10.1002/jcph.2325.
 
9.
Meyer F, Weil-Verhoeven D, Prati C, et al. Safety of biologic treatments in solid organ transplant recipients: a systematic review. Semin Arthritis Rheum 2021; 51: 1263–1273, DOI: 10.1016/j.semarthrit.2021.08.013.
 
10.
Garrouste C, Anglicheau D, Kamar N, et al. Anti-TNF therapy for chronic inflammatory disease in kidney transplant reci­pients: clinical outcomes. Medicine (Baltimore) 2016; 95: e5108, DOI: 10.1097/MD.0000000000005108.
 
11.
Panagakis A, Bellos I, Grigorakos K, et al. Recurrence of idio­pathic membranous nephropathy in the kidney allograft: a systematic review. Biomedicines 2024; 12: 739, DOI: 10.3390/ biomedicines12040739.
 
12.
Schrezenmeier E, Budde K, Staeck O, et al. Incidence of infectious disease and malignancies after rituximab therapy in kidney transplant recipients: results from a cohort in Germany. Transplant Proc 2017; 49: 2269–2273, DOI: 10.1016/ j.transproceed.2017.09.042.
 
13.
Cabezas L, Jouve T, Malvezzi P, et al. Tocilizumab and active antibody-mediated rejection in kidney transplantation: a lite­rature review. Front Immunol 2022; 13: 839380, DOI: 10.3389/fimmu.2022.839380.
 
14.
Mirioglu S, Dirim AB, Bektas M, et al. Efficacy and safety of interleukin-1 blockers in kidney transplant recipients with familial Mediterranean fever: a propensity score-matched cohort study. Nephrol Dial Transplant 2023; 38: 1327–1336, DOI: 10.1093/ndt/gfac335.
 
15.
Yazısız V, Yılmaz VT, Uçar İ, et al. The use of anti-interleukin-1 agents and tumor necrosis factor-alpha inhibitors in renal transplant recipients. Arch Rheumatol 2021; 36: 366–374, DOI: 10.46497/ArchRheumatol.2021.8500.
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top